Mirum Pharmaceuticals Inc. (MIRM), which reported global net product sales growth of 137% in the first quarter of 2024, is progressing steadily towards achieving its annual growth objective of 66% to 72%.
The company has three approved medications - Livmarli oral solution, Cholbam capsules, and Chenodal tablets.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com